58,906 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 58,906 shares of the biopharmaceutical company’s stock, valued at approximately $33,121,000. Rakuten Investment Management Inc. owned 0.06% of Regeneron Pharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in shares of Regeneron Pharmaceuticals by 1.4% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 108,044 shares of the biopharmaceutical company’s stock worth $60,750,000 after purchasing an additional 1,486 shares during the last quarter. Chicago Partners Investment Group LLC bought a new position in Regeneron Pharmaceuticals in the third quarter worth about $531,000. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at about $93,000. Seizert Capital Partners LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 14.9% in the 3rd quarter. Seizert Capital Partners LLC now owns 98,790 shares of the biopharmaceutical company’s stock valued at $55,547,000 after buying an additional 12,810 shares in the last quarter. Finally, Sage Mountain Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $514,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 8,431 shares of company stock worth $5,733,521. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $733.78 on Wednesday. The stock’s fifty day moving average price is $751.62 and its 200 day moving average price is $640.00. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. The company has a market cap of $77.12 billion, a price-to-earnings ratio of 17.57, a PEG ratio of 1.92 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the previous year, the business earned $12.46 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 8th. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Cantor Fitzgerald increased their price objective on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Scotiabank boosted their target price on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Finally, Guggenheim increased their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $791.05.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.